Prostate cancer
-
healthDarolutamide Shows Cognitive Edge Over Enzalutamide in Prostate Cancer
New data from the ARACOG trial shows darolutamide causes less cognitive decline than enzalutamide in prostate cancer patients.
-
healthTALAPRO-3 Shows PARP Inhibitor Combo Delays Prostate Cancer Progression
Phase 3 trial results presented at ASCO 2026 show talazoparib plus enzalutamide significantly improves radiographic progression-free survival in HRR-deficient metastatic castration-sensitive prostate cancer.
-
healthLow Testosterone Predicts High-Grade Prostate Cancer in Men on Active Surveillance
A new study reveals that low baseline testosterone significantly increases the risk of progression to high-grade prostate cancer for men undergoing active surveillance.
-
healthPRECISE MRI Score Refines Prostate Cancer Monitoring
New study shows PRECISE scoring on MRI helps predict biopsy progression in men with low-risk prostate cancer on active surveillance.
-
healthLifestyle Choices Significantly Impact Prostate Cancer Patient Cognition
New study links physical activity, smoking, and BMI to cognitive and emotional well-being in men with prostate cancer, emphasizing modifiable behaviors.
-
worldNetanyahu Reveals Treatment for Early-Stage Prostate Cancer, Cites Security Concerns
Israeli Prime Minister Benjamin Netanyahu disclosed he underwent treatment for early-stage prostate cancer 18 months ago, delaying the announcement for national security reasons.
-
healthLiquid Biopsy Shows Promise for High-Risk Localized Prostate Cancer
New study suggests liquid biopsies offer a less invasive, more reliable genomic profiling alternative for localized prostate cancer, potentially guiding treatment decisions.
-
healthAI vs. Radiologists: New Trial Tackles Prostate Cancer Detection
A major international trial, PARADIGM, is set to compare AI's accuracy against expert radiologists for detecting clinically significant prostate cancer using MRI.